Literature DB >> 8162070

HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity.

R J Apple1, H A Erlich, W Klitz, M M Manos, T M Becker, C M Wheeler.   

Abstract

Cervical carcinoma is now known to be associated with human papillomaviruses (HPV), but the evidence for a link with specific HLA loci is controversial. The role of genetic variation at the HLA class II loci and among HPV types in cervical carcinoma was investigated by PCR DNA amplification and oligonucleotide probe typing of paraffin-embedded invasive cervical cancer tissue from Hispanic patients and of cervical swabs from Hispanic controls. Certain HLA class II haplotypes (such as DRB1*1501-DQB1*0602) were associated significantly, while DR13 haplotypes were negatively associated with cervical carcinoma. These associations are HPV16-type specific. These results suggest that specific HLA class II haplotypes may influence the immune response to specific HPV-encoded epitopes and affect the risk of cervical neoplasia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162070     DOI: 10.1038/ng0294-157

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  44 in total

1.  Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles.

Authors:  S Chaudhuri; A Cariappa; M Tang; D Bell; D A Haber; K J Isselbacher; D Finkelstein; D Forcione; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses.

Authors:  April L Ferre; Peter W Hunt; Delandy H McConnell; Megan M Morris; Juan C Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

3.  The role of human leucocyte antigen genes in the development of malignant disease.

Authors:  W M Howell; D B Jones
Journal:  Clin Mol Pathol       Date:  1995-12

4.  HLA class II polymorphism: protective or risk factors to breast cancer in Tunisia?

Authors:  Amal Baccar Harrath; Besma Yacoubi Loueslati; Wafa Troudi; Slama Hmida; Syrine Sedkaoui; Amel Dridi; Afef Jridi; Farhat Ben Ayed; Khaled Ben Rhomdhane; Amel Ben Ammar Elgaaied
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

5.  An empirical method for the prediction of T-cell epitopes.

Authors:  M P Davenport; I A Ho Shon; A V Hill
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Amino acid residues in the carboxy-terminal region of cottontail rabbit papillomavirus E6 influence spontaneous regression of cutaneous papillomas.

Authors:  Jiafen Hu; Nancy M Cladel; Martin D Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B.

Authors:  H M Diepolder; M C Jung; E Keller; W Schraut; J T Gerlach; N Grüner; R Zachoval; R M Hoffmann; C A Schirren; S Scholz; G R Pape
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

8.  Molecular anatomy of mouse hepatitis virus persistence: coevolution of increased host cell resistance and virus virulence.

Authors:  W Chen; R S Baric
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma.

Authors:  Enrique Lerma; Marisa Romero; Alberto Gallardo; Cristina Pons; Josefina Muñoz; Josefina Fuentes; Belen Lloveras; Lluis Catasus; Jaime Prat
Journal:  Virchows Arch       Date:  2007-11-14       Impact factor: 4.064

10.  Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs.

Authors:  Wei Song; Avima M Ruder; Liangyuan Hu; Yufeng Li; Rong Ni; Wenshuo Shao; Richard A Kaslow; MaryAnn Butler; Jianming Tang
Journal:  PLoS One       Date:  2009-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.